iRGD肽
| 中文名称 | iRGD肽 |
|---|---|
| 中文同义词 | 肿瘤多肽H-CYS-ARG-GLY-ASP-LYS-GLY-PRO-ASP-CYS-OH;H-CYS-CYS-ARG-GLY-ASP-LYS-GLY-PRO-ASP-CYS-OH(DISULFIDE BRIDGE:CYS2-CYS10);化合物IRGD PEPTIDE;IRGD肽;罗恩 肿瘤多肽H-CYS-ARG-GLY-ASP-LYS-GLY-PRO-ASP-CYS-OH R113664-5mg;iRGD peptide试剂;iRGD peptide试剂;L-半胱氨酸,L-半胱氨酰-L-精氨酰甘氨酰-L-α-天门冬氨酰-L-赖氨酰甘氨酰-L-脯氨酰-L-α-天门冬氨酰基,环状(1→9)-二硫键 |
| 英文名称 | iRGD |
| 英文同义词 | iRGD;L-Cysteine, L-cysteinyl-L-arginylglycyl-L-α-aspartyl-L-lysylglycyl-L-prolyl-L-α-aspartyl-, cyclic (1→9)-disulfide;iRGD TFA;iRGD peptide TFA salt;c(CRGDKGPDC);inhibit,Inhibitor,iRGD peptide,Integrin;2,2'-((3S,6R,11R,14S,20S,23S,31aS)-11-amino-23-(4-aminobutyl)-6-carboxy-14-(3-guanidinopropyl)-1,4,12,15,18,21,24,27-octaoxooctacosahydro-1H-pyrrolo[2,1-j][1,2]dithia[5,8,11,14,17,20,23,26]octaazacyclononacosine-3,20-diyl)diacetic acid;iGRD peptide |
| CAS号 | 1392278-76-0 |
| 分子式 | C35H57N13O14S2 |
| 分子量 | 948.04 |
| EINECS号 | |
| 相关类别 | 多肽-客户肽;对照品;目录多肽 |
| Mol文件 | 1392278-76-0.mol |
| 结构式 |  |
iRGD肽 性质
| 密度 | 1.68±0.1 g/cm3(Predicted) |
|---|---|
| 储存条件 | -20°C, protect from light |
| 溶解度 | DMSO: Soluble: =10 mg/mlPBS (pH 7.2): Soluble: =10 mg/ml |
| 形态 | 固体 |
| 酸度系数(pKa) | 2.92±0.70(Predicted) |
| 颜色 | 白色至米白色 |
| 水溶解性 | Water : ≥ 50 mg/mL (52.74 mM) |
| 序列 | H-Cys-Arg-Gly-Asp-Lys-Gly-Pro-Asp-Cys-OH(Disulfide bridge: Cys1-Cys9) |
Integrin
iRGD peptide-mediated tumor penetration occurs in three steps: binding to αv-integrins on tumor vasculature or tumor cells, exposure by proteolysis of a C-terminal motif that binds to neuropilin-1 (NRP-1) and cell internalization. iRGD peptide inserted in the ICOVIR15K fiber C terminus enhances binding and internalization only in MCF7 cells, which express NRP-1 and integrins. iRGD insertion does not impair virus infection and replication. iRGD peptide alone has no obvious effect on gastric cancer cells, and when combined with 5-FU, iRGD peptide (0.3 μmol/mL) enhances the chemotherapy efficacy of 5-FU on gastric cancer cells through NRP1.
iRGD inserted in the oncolytic adenovirus ICOVIR15K (ICOVIR15K-iRGD) enhances early adenovirus dissemination through the tumor mass and elevates the antitumor effect in mice. iRGD (4 mmol/kg, i.v.) in combination with 5-FU significantly suppresses the tumor growth in nude mice bearing human gastric cancer cells.
纯度(HPLC) ≥98.0%
醋酸根含量≤12.0%
水分含量≤8.0%
肽含量≥80.0%
内毒素≤50EU/mg
氨基酸组成分析≤±10%
安全信息
| 更新日期 | 产品编号 | 产品名称 | CAS号 | 包装 | 价格 |
|---|---|---|---|---|---|
| 2026/09/15 | HY-P0122 | iRGD肽 iRGD peptide | 1392278-76-0 | 1 mg | 900元 |
| 2026/09/15 | HY-P0122 | iRGD肽 iRGD peptide | 1392278-76-0 | 2 mg | 1530元 |